An Organometallic Inhibitor for Glycogen Synthase Kinase 3

Citations Over TimeTop 10% of 2004 papers

Abstract

Replacing natural products with kinetically inert metal complexes may lead to a new class of therapeutics in which a metal center plays the role of an innocent bystander, organizing the orientation of the organic ligands in the receptor space. As an example of this approach, a ruthenium complex is described that copies the binding mode of indolocarbazole protein kinase inhibitors and serves as a reversible, low-nanomolar inhibitor for glycogen synthase kinase 3 (GSK-3).

Related Papers

• → Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3(1997)482 cited
• → Synthesis of a Glycogen Synthase Kinase-3 Inhibitor(2010)2 cited
• [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].(2007)
• Role of glycogen synthase kinase-3 in the pathogenesis of Alzheimer's disease(2011)